Lin Wu
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 128
- Lung Cancer Research Studies 50
- Cancer Immunotherapy and Biomarkers 41
- Colorectal Cancer Treatments and Studies 16
- Peptidase Inhibition and Analysis 13
-
- Lung Cancer Treatments and Mutations 105
- Lung Cancer Diagnosis and Treatment 15
- Co-authors
- Masaaki Moriya (3 shared papers)Arthur P. Grollman (3 shared papers)Julie Tsai (4 shared papers)Robert J. Turesky (2 shared papers)Tony S.K. Mok (5 shared papers)Britta Weber (3 shared papers)Wen Wei (3 shared papers)Boe Sandahl Sørensen (3 shared papers)
- Journals
- Annals of Oncology (26 papers)Journal of Thoracic Oncology (14 papers)Lung Cancer (10 papers)Blood (10 papers)Translational Lung Cancer Research (9 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Lin Wu
257 papers receiving 12.6k citations
Lin Wu's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 5.5k
- Pulmonary and Respiratory Medicine 4.3k
- Cancer Research 1.8k
- Genetics 1.2k
- Pathology and Forensic Medicine 1.8k
Countries citing papers authored by Lin Wu
This map shows the geographic impact of Lin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Wu more than expected).
Fields of papers citing papers by Lin Wu
This network shows the impact of papers produced by Lin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Wu. The network helps show where Lin Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Lin Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 276 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Hit paper breakdown → | 2013 | 561 |
| 2 | Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma Hit paper breakdown → | 2021 | 558 |
| 3 | Aristolochic acid and the etiology of endemic (Balkan) nephropathy Hit paper breakdown → | 2007 | 511 |
| 4 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 503 |
| 5 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial Hit paper breakdown → | 2014 | 436 |
| 6 | Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Hit paper breakdown → | 2015 | 428 |
| 7 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Hit paper breakdown → | 2017 | 424 |
| 8 | Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial Hit paper breakdown → | 2022 | 365 |
| 9 | Aristolochic acid-associated urothelial cancer in Taiwan Hit paper breakdown → | 2012 | 351 |
| 10 | Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer Hit paper breakdown → | 2022 | 335 |
| 11 | 2012 | 326 | |
| 12 | 2019 | 302 | |
| 13 | Perioperative Nivolumab in Resectable Lung Cancer Hit paper breakdown → | 2024 | 288 |
| 14 | Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) Hit paper breakdown → | 2021 | 247 |
| 15 | Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer Hit paper breakdown → | 2024 | 233 |
| 16 | 2020 | 205 | |
| 17 | 2013 | 198 | |
| 18 | 2011 | 190 | |
| 19 | 2003 | 188 | |
| 20 | 2008 | 182 |
About Lin Wu
Lin Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Genetics, having authored 276 papers that have together received 12.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (105 papers), Lung Cancer Research Studies (50 papers), Cancer Immunotherapy and Biomarkers (41 papers), Cancer Genomics and Diagnostics (17 papers), Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Diagnosis and Treatment (15 papers), Lymphoma Diagnosis and Treatment (13 papers) and Peptidase Inhibition and Analysis (13 papers). The work is most often cited by research in Oncology (5.5k citations), Pulmonary and Respiratory Medicine (4.3k citations), Cancer Research (1.8k citations), Genetics (1.2k citations) and Pathology and Forensic Medicine (1.8k citations). Lin Wu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Masaaki Moriya, Arthur P. Grollman, Julie Tsai, Robert J. Turesky, Tony S.K. Mok, Britta Weber, Wen Wei, Boe Sandahl Sørensen, Peter Meldgaard and Yi-Long Wu. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Blood and Translational Lung Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.